Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on December 20, 2021, regarding events occurring on December 14, 2021. The filing details the appointment of Yvonne L. Greenstreet, MBChB, MBA, as the Company's Chief Executive Officer, effective January 1, 2022, succeeding her previous role as President and Chief Operating Officer.
Key Financial Metrics
This filing does not contain general financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The financial information provided is limited to the specific compensation terms of the new CEO employment agreement.
- 2022 Annual Base Salary: $850,000
- 2022 Target Bonus: 100% of base salary ($850,000)
- Initial Equity Award (Stock Options): Grant Date fair value of $5,000,000
- Future Equity Awards (Expected Feb 2022): Stock options with a Grant Date fair value of $2,500,000 and Performance Stock Units (PSUs) with a Grant Date fair value of $7,500,000
- One-Time Cash Award: $250,000 (subject to clawback provisions)
Material Changes
The primary material change is the leadership transition and the associated executive compensation structure:
- Leadership Change: Dr. Greenstreet transitions from President and COO to CEO.
- Compensation Structure: A new employment agreement was executed with an initial term through December 31, 2023, with automatic one-year renewals.
- Relocation Benefits: Effective January 1, 2022, the Company will cease providing housing or travel relocation benefits to Dr. Greenstreet.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, market outlook, or general risk factors. However, it outlines specific contingencies related to the CEO's employment termination:
- Clawback Provision: If Dr. Greenstreet terminates without "Good Reason" or is terminated for "Cause" within 24 months, she must repay all or a portion of the $250,000 one-time cash award.
- Termination without Cause/Good Reason (Pre-Change in Control): No cash severance is provided. Unvested equity continues to vest until the second anniversary of termination, and stock options remain exercisable until the earlier of the second anniversary or original expiration.
- Termination within 18 Months of Change in Control: Dr. Greenstreet would receive a lump sum cash payment equal to two times the sum of her annual base salary and target bonus, up to 24 months of health insurance contributions, and immediate acceleration of all outstanding stock options and awards.
Investor Verification Checklist
- Verify the exact vesting schedule for the $5,000,000 initial stock option grant (25% on first anniversary, then 6.25% quarterly).
- Confirm the performance criteria applicable to the $7,500,000 PSU award, which aligns with the Management Board awards expected in February 2022.
- Review the full Employment Agreement (Exhibit 10.1) for precise definitions of "Good Reason," "Cause," and "Change in Control."
- Monitor the Company's future filings for the actual grant date and terms of the February 2022 equity awards.